Rosen , Julie R
Osobn daje sa spracvaj vlune v rmci innosti Prevdzkovatea, konkrtne na tieto ely: 5
If youre unsure where to start, OnPoint Nutritions team of registered dietitians can help
Lower doses around 250mg are common for maintenance or preventing deficiency
The guidelines state, GLP-1 RAs may be considered for weight-loss in patients who have completed cancer therapy and may be considered with caution for patients on stable endocrine-based cancer therapies based on limited observational safety data. They also say, GLP-1 RAs cannot be recommended currently for patients receiving or initiating chemotherapies and/or immunotherapies due to lack of safety and outcomes data. Iyengar is director of Survivorship Services at Winship Cancer Institute of Emory University, a clinical member of Winships Glenn Family Breast Center, an associate professor and co-director of the Breast Medical Oncology Program in the Department of Hematology and Medical Oncology at Emory University School of Medicine, and co-editor-in-chief of the journal ONCOLOGY
To address these concerns, it is important to monitor patient condition, educate them on the method of medication, make dose adjustments as necessary, and develop safer and more tolerable formulations of GLP-1-based therapies
